

GRADUATE CERTIFICATE IN HEALTH PRODUCTS REGULATION GMS5116: POST-MARKET ACTIVITIES FOR PHARMACEUTICALS

21 February – 25 February 2022

Conducted via Zoom

Overall objectives of the workshop

- Build and enhance capability for the key activities and roles essential for effective postmarket control of pharmaceutical products.
- Promote opportunities for optimisation of post-market surveillance networks and collaboration, handling of substandard and falsified pharmaceuticals within ASEAN region.

Learning outcomes

- Describe the post-market surveillance and enforcement activities to monitor and ensure the quality and safety of pharmaceutical products
- Explain the role of good manufacturing practices (GMP) and good storage and distribution practices (GSDP) in safeguarding the quality of approved pharmaceutical products across the product lifecycle
- List the national and international platforms and initiatives that are supporting postmarket regulatory activities to enhance supply chain integrity of pharmaceutical products and facilitate timely interventions

Copyright statement

This material is the property of the Duke-NUS Medical School. It is not to be duplicated or distributed without written permission of the Executive Director and the management team of the Centre of Regulatory Excellence of Duke-NUS Medical School.

Graduate Certificate in Health Products Regulation GMS5116 Post-Market Activities for Pharmaceuticals

21 - 25 February 2022

Day 1 – February 21, Mon

8.30am Welcome and workshop briefing Asst Prof James Leong Head, Health Products and Regulatory Science Centre of Regulatory Excellence (CoRE) Duke-NUS Medical School 9.00am Group activity Mr Osman Mohamad Senior Associate Centre of Regulatory Excellence (CoRE) Duke-NUS Medical School 9.00am Break Image: Contre of Regulatory Excellence (CoRE) Duke-NUS Medical School 9.00am Break Dr Souly Phanouvong Senior Technical Advisor Regulatory Systems Strengthening	Time	Agenda	Faculty
9.30am Break 10.00am Role of post-market surveillance programme to ensure quality and supply chain integrity of pharmaceutical products Dr Souly Phanouvong Senior Technical Advisor Regulatory Systems Strengthening United States Pharmacopeial Convention (USP) Session 1: Ensuring pharmaceutical product guality and supply chain integrity of pharmaceutical surveillance) Product sampling and testing strategy Dr Souly Phanouvong Session 1: Ensuring pharmaceutical product quality and supply chain security - GMP 11.15pm Role of Good Manufacturing Practices (GMP) Mr Vimal Sachdeva Technical Officer (Expert Inspector) Prequalification Team World Health Organization (WHO) 12.30pm Lunch Mr Vimal Sachdeva Technical Officer (Expert Inspector) Prequalification Team World Health Organization (WHO) 13.30pm Good Practices in Production and Quality Control • Active Pharmaceutical Ingredient • Finished Pharmaceutical Product Mr Vimal Sachdeva WHO 3.30pm Type of GMP inspections Mr Vimal Sachdeva WHO 3.30pm WHO Prequalification Programme (WHO PQP) • Background of PQP • WHO role in facilitating regulatory reliance for cGMP inspection • WHO rurent GMP and supplementary guidelines Mr Vimal Sachdeva WHO 4.30pm A global effort to improve GMP standards – Initiatives from TBC	8.30am	Welcome and workshop briefing	Head, Health Products and Regulatory Science Centre of Regulatory Excellence (CoRE)
10.00am Role of post-market surveillance programme to ensure quality and supply chain integrity of pharmaceutical products Dr Souly Phanouvong 9 Supporting infrastructures (e.g. application of GMP principles, GSDP, national/international surveillance) Product sampling and testing strategy Senior Technical Advisor Regulatory Systems Strengthening United States Pharmacopeial Convention (USP) 9 Product sampling and testing strategy Section 1: Ensuring pharmaceutical product quality and supply chain security - GMP 11.15pm Role of Good Manufacturing Practices (GMP) Mr Vimal Sachdeva Technical Officer (Expert Inspector) Prequalification Team World Health Organization (WHO) 12.30pm Lunch Mr Vimal Sachdeva 1.30pm Good Practices in Production and Quality Control Mr Vimal Sachdeva WHO 2.30pm Type of GMP inspections Mr Vimal Sachdeva WHO 3.30pm Break WHO Prequalification Programme (WHO PQP) Mr Vimal Sachdeva WHO 9 WHO role in facilitating regulatory reliance for cGMP inspection procedures worldwide WHO 9 WHO role in facilitating regulatory reliance for cGMP inspection WHO 4.30pm A global effort to improve GMP standards – Initiatives from TBC	9.00am	Group activity	Senior Associate Centre of Regulatory Excellence (CoRE)
and supply chain integrity of pharmaceutical products Senior Technical Advisor Regulatory Systems Strengthening Principles, GSDP, national/international surveillance) Senior Technical Advisor Product sampling and testing strategy Product sampling and testing strategy Senior Technical Advisor Session 1: Ensuring pharmaceutical product quality and supply chain security - GMP Mr Vimal Sachdeva 11.15pm Role of Good Manufacturing Practices (GMP) Mr Vimal Sachdeva 12.30pm Lunch Mr Vimal Sachdeva 1.30pm Good Practices in Production and Quality Control Mr Vimal Sachdeva VHO - Active Pharmaceutical Product WHO 2.30pm Type of GMP inspections Mr Vimal Sachdeva 3.30pm WHO Prequalification Programme (WHO PQP) Background of PQP • Background of PQP WHO efforts towards harmonizing cGMP inspection procedures worldwide WHO • WHO role in facilitating regulatory reliance for cGMP inspection WHO WHO • WHO current GMP and supplementary guidelines TBC	9.30am	Break	
11.15pmRole of Good Manufacturing Practices (GMP)Mr Vimal Sachdeva Technical Officer (Expert Inspector) Prequalification Team World Health Organization (WHO)12.30pmLunchMr Vimal Sachdeva World Health Organization (WHO)1.30pmGood Practices in Production and Quality Control • Active Pharmaceutical Ingredient • Finished Pharmaceutical ProductMr Vimal Sachdeva WHO2.30pmType of GMP inspectionsMr Vimal Sachdeva WHO3.00pmBreak • Background of PQP • WHO efforts towards harmonizing cGMP inspection procedures worldwide • WHO role in facilitating regulatory reliance for cGMP inspection • WHO current GMP and supplementary guidelinesMr Vimal Sachdeva WHO4.30pmA global effort to improve GMP standards – Initiatives fromTBC	10.00am	 and supply chain integrity of pharmaceutical products Supporting infrastructures (e.g. application of GMP principles, GSDP, national/international surveillance) 	Senior Technical Advisor Regulatory Systems Strengthening United States Pharmacopeial Convention
11.15pm Role of Good Manufacturing Practices (GMP) Mr Vimal Sachdeva Technical Officer (Expert Inspector) Prequalification Team World Health Organization (WHO) 12.30pm Lunch 1.30pm Good Practices in Production and Quality Control • Active Pharmaceutical Ingredient • Finished Pharmaceutical Product Mr Vimal Sachdeva WHO 2.30pm Type of GMP inspections Mr Vimal Sachdeva WHO 3.00pm Break • Background of PQP • WHO efforts towards harmonizing cGMP inspection procedures worldwide • WHO role in facilitating regulatory reliance for cGMP inspection • WHO current GMP and supplementary guidelines Mr Vimal Sachdeva WHO 4.30pm A global effort to improve GMP standards – Initiatives from TBC	Session 1	Ensuring pharmaceutical product guality and supply chain se	ecurity - GMP
1.30pmGood Practices in Production and Quality Control Active Pharmaceutical IngredientFinished Pharmaceutical Product Mr Vimal Sachdeva WHO2.30pmType of GMP inspectionsMr Vimal Sachdeva WHO3.00pmBreakMr Vimal Sachdeva WHO3.30pmWHO Prequalification Programme (WHO PQP) Background of PQPWHO efforts towards harmonizing cGMP inspection procedures worldwideWHO role in facilitating regulatory reliance for cGMP inspectionWHO current GMP and supplementary guidelines Mr Vimal Sachdeva WHO4.30pmA global effort to improve GMP standards – Initiatives fromTBC		Role of Good Manufacturing Practices (GMP)	Mr Vimal Sachdeva Technical Officer (Expert Inspector) Prequalification Team
 Active Pharmaceutical Ingredient Finished Pharmaceutical Product WHO Type of GMP inspections Mr Vimal Sachdeva WHO Sachdeva WHO Break WHO Prequalification Programme (WHO PQP) Background of PQP WHO efforts towards harmonizing cGMP inspection procedures worldwide WHO role in facilitating regulatory reliance for cGMP inspection WHO current GMP and supplementary guidelines 4.30pm A global effort to improve GMP standards – Initiatives from 	12.30pm		
3.00pm Break WHO 3.30pm WHO Prequalification Programme (WHO PQP) Mr Vimal Sachdeva • Background of PQP • WHO efforts towards harmonizing cGMP inspection procedures worldwide WHO • WHO role in facilitating regulatory reliance for cGMP inspection • WHO current GMP and supplementary guidelines WHO 4.30pm A global effort to improve GMP standards – Initiatives from TBC	1.30pm	Active Pharmaceutical Ingredient	
 3.30pm WHO Prequalification Programme (WHO PQP) Background of PQP WHO efforts towards harmonizing cGMP inspection procedures worldwide WHO role in facilitating regulatory reliance for cGMP inspection WHO current GMP and supplementary guidelines 4.30pm A global effort to improve GMP standards – Initiatives from TBC 	2.30pm	Type of GMP inspections	
 3.30pm WHO Prequalification Programme (WHO PQP) Background of PQP WHO efforts towards harmonizing cGMP inspection procedures worldwide WHO role in facilitating regulatory reliance for cGMP inspection WHO current GMP and supplementary guidelines 4.30pm A global effort to improve GMP standards – Initiatives from 	3.00pm	Break	
		 Background of PQP WHO efforts towards harmonizing cGMP inspection procedures worldwide WHO role in facilitating regulatory reliance for cGMP inspection 	
5.30pm End	•	PIČ/S	ТВС

Day 2 – February 22, Tue

Time	Agenda	Faculty
9.00am	Individual and Group Assessment I	CoRE Education team
10.00am	Break	
Session 2	: Ensuring pharmaceutical product quality and supply chain se	ecurity – GSDP
10.30am	 Maintaining supply chain security Supply chain security programmes Handling of supply chain security breaches Detection technologies with focus on suspected substandard and falsified pharmaceutical products 	Dr Souly Phanouvong USP
11.30am	Laboratory support and capacity building	Dr Souly Phanouvong USP
12.30pm	Lunch	
1.30pm	Case discussion: Corrective Actions and Preventive Actions (CAPA)	Asst Prof James Leong CoRE
3.30pm	Break	
4.00pm	Practicum I: GMP	<u>Content Expert</u> Mr Vimal Sachdeva WHO
5.30pm	End	

Day 3 – February 23, Wed

Time	Agenda	Faculty			
9.00am	Individual and Group Assessment II	CoRE Education team			
10.00am	Break				
	n 3: Ensuring pharmaceutical product quality and supply chain security – Post-market surveillance				
	activities for approved medicinal products				
10.30am	 Pharmaceutical quality surveillance in Singapore Purposes Sampling criteria Laboratory testing 	Ms Yang Silin Senior Regulatory Specialist Vigilance and Compliance Branch (VCB) Health Products Regulation Group (HPRG) Health Sciences Authority (HSA) Singapore			
11.15am	 Reporting of therapeutic product defects and recall Classification of product quality defects Level of recalls Investigation, corrective and preventive actions 	Mr Choong Chih Tzer Senior Regulatory Specialist Vigilance and Compliance Branch (VCB) Health Products Regulation Group (HPRG) Health Sciences Authority (HSA) Singapore			
12.00pm	Lunch				
1.30pm	Practicum II: Handling of pharmaceutical product quality defects	<u>Content Experts</u> Ms Yang Silin			
		HSA, Singapore Mr Choong Chih Tzer HSA, Singapore			
3.30pm	Break	HSA, Singapore Mr Choong Chih Tzer HSA, Singapore			
3.30pm 4.00pm	Break Product Quality Surveillance	HSA, Singapore Mr Choong Chih Tzer			
		HSA, Singapore Mr Choong Chih Tzer HSA, Singapore Ms Ruth Lee Associate Director Public Policy and Regulatory Affairs Global External Affairs, APAC United States Pharmacopeial Convention			

Day 4 – February 24, Thurs

Time	Agenda	Faculty
9.00am	Individual and Group Assessment III	CoRE Education team
10.00am	Break	
10.30am	Case Discussion: Considerations for preparing a sampling list	Asst Prof James Leong CoRE
Session 4	Ensuring pharmaceutical product quality and supply chain sec	curity – Surveillance activities for
Counterfe	it, Substandard and Falsified medicinal products	
11.30am	 Trend Observation on Counterfeits (CF), Substandard and Falsified (SF) Medicines in the Asia-Pacific Region What are CF and SF medicines Hot spot areas in the Asia-Pacific region and the contributory factors Impact of CF and SF medicines to public health 	Mr Ramesh Raj Kishore Regional Director – Asia Pacific Pharmaceutical Security Institute Singapore
12.30pm	Lunch	
1.30pm	Practicum III: Detection of SF medicinal product	Content Expert Mr Ramesh Raj Kishore Pharmaceutical Security Institute
3.30pm	Break	
4.00pm	Regulatory systems strengthening to mitigate issues of SF	Dr Valerio Reggi Visiting Expert CoRE, Consultant Drug Regulatory Matters & Pharmaceutical Policy
4.45pm	Group Activity – Preparation for panel discussion	CoRE Education team
5.30pm	End	

Day 5 – February 25, Fri

Time	Agenda	Faculty
Session 4:	Ensuring pharmaceutical product quality and supply chain securi	ity – Enforcement activities
9.00am	End-of-Module (EOM) assessment	CoRE Education team
10.00am	Discussion for EOM	CoRE Education team
10.30am	Break	
11.00am	 Enforcement efforts against SF and illegal sales of medicinal products in ASEAN Magnitude of issue in ASEAN landscape Types of operations carried out Collaboration with other agencies intra- and inter-countries 	Mr Jonathan Selvasegaram Asia Pacific Manager and Legal Counsel React
11.30am	 Global enforcement efforts against SF and illegal sales of medicinal products Magnitude of issues worldwide Role of INTERPOL Strategies to combat existing and emerging global threat 	Ms Ruth Lee USP
12.30pm	Lunch	
2.00pm	Case discussion: Enforcement operations against SF medicines	CoRE Education team
3.30pm	Break	
4.00pm	Panel discussion – Facilitating a regional approach in tackling SF issues	Panellist Ms Ruth Lee USP Mr Ramesh Raj Pharmaceutical Security Institute Mr Jonathan Selvasegaram React
5.00pm	Workshop conclusion	A/Prof Silke Vogel Senior Associate Dean Graduate Studies Deputy Director Centre of Regulatory Excellence, Head Centre for Lifelong Learning, Duke-NUS Medical School
5.30pm	End	